Abstract
Background: Increasing number of studies has reported that Atpase family AAA domain-containing 2 (ATAD2) is nuclear coactivator, which is associated with tumor cell proliferation and invasion. Previous studies have demonstrated conflicting results on the relationship between high ATAD2 expression and clinicopathological characteristics of the tumors or patients’ survival outcomes. Considering the discordant results of published studies, we performed a metaanalysis to evaluate the ATAD2 expression in predicting prognosis, and to assess the relationship between high ATAD2 expression and clinicopathological parameters.Methods: We systematically searched electronic database of PubMed, Web of Science and Embase, and selected all immunohistochemical studies of hepatocellular cancer specimens for ATAD2, to analyze the relationship between high ATAD2 expression and prognosis of hepatocellular cancer patients. Pooled data of eligible studies together from individual studies and analyzed data using STATA software to perform this meta-analysis.Results: A total of 5 studies with 719 liver cancer patients were included. ATAD2 protein overexpression wassignificantly correlated with poorer overall survival (HR 3.53, 95% CI: 1.87-6.63, P = 0.000). In addition, high ATAD2 expression was also negatively related with tumor stage [RR, relative risk: 1.46 (95% CI: 1.30-1.64); P < 0.001], as well as tumor size [RR: 1.23(95% CI: 1.06-1.43); P < 0.001], and tumor recurrence [RR: 1.34 (95% CI: 1.05-1.72); P < 0.001].Conclusions: These data suggested that immunohistochemical determination of ATAD2 Protein might be aprognostic biomarker for the patients of hepatocellular cancer.
Highlights
ATPase family AAA domain-containing protein 2 (ATAD2), listed as pro2000, ANCCA (AAA+ nuclear coregulator cancer-associated), shares the conserved region of ~ 220 amino acids where contains an ATPbinding site with other members of the ATPases family
The results showed that Atpase family AAA domain-containing 2 (ATAD2) protein expressed in the cytoplasm or cell nucleus in cancer specimens by immunohistochemistry (IHC)
Nineteen fulltext articles were assessed for eligibility after removing the studies of cell experiments, not in English or not for survival
Summary
ATPase family AAA domain-containing protein 2 (ATAD2), listed as pro2000, ANCCA (AAA+ nuclear coregulator cancer-associated), shares the conserved region of ~ 220 amino acids where contains an ATPbinding site with other members of the ATPases family. ATAD2, as a critical oncogene [1], is associated with tumor cell proliferation and invasion. It contains two J Cancer Biol Therap, 5(1): 280-289 (2019). Taghavi A et al. Increasing number of studies has reported that Atpase family AAA domain-containing 2 (ATAD2) is nuclear coactivator, which is associated with tumor cell proliferation and invasion. Previous studies have demonstrated conflicting results on the relationship between high ATAD2 expression and clinicopathological characteristics of the tumors or patients’ survival outcomes. Methods: We systematically searched electronic database of PubMed, Web of Science and Embase, and selected all immunohistochemical studies of hepatocellular cancer specimens for ATAD2, to analyze the relationship between high ATAD2 expression and prognosis of hepatocellular cancer patients. Conclusions: These data suggested that immunohistochemical determination of ATAD2 Protein might be a prognostic biomarker for the patients of hepatocellular cancer
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
